Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 239 entries
Sorted by: Best Match Show Resources per page
"If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C.

Digestive diseases and sciences

Evon DM, Kim HP, Edwards A, Carda-Auten J, Reeve BB, Golin CE, Fried MW.
PMID: 33528686
Dig Dis Sci. 2022 Jan;67(1):100-120. doi: 10.1007/s10620-021-06829-2. Epub 2021 Feb 02.

BACKGROUND: Patients' motivations for undergoing direct-acting antiviral (DAA) therapy for chronic hepatitis C may include anticipation of treatment benefits not well described in the literature.AIMS: Evaluate patients' anticipated and actualized improvements in several domains of functioning before and after...

Cite
Evon DM, Kim HP, Edwards A, et al. "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. Dig Dis Sci. 2021;67(1):100-120doi: 10.1007/s10620-021-06829-2.
Evon, D. M., Kim, H. P., Edwards, A., Carda-Auten, J., Reeve, B. B., Golin, C. E., & Fried, M. W. (2022). "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. Digestive diseases and sciences, 67(1), 100-120. https://doi.org/10.1007/s10620-021-06829-2
Evon, Donna M, et al. ""If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C." Digestive diseases and sciences vol. 67,1 (2022): 100-120. doi: https://doi.org/10.1007/s10620-021-06829-2
Evon DM, Kim HP, Edwards A, Carda-Auten J, Reeve BB, Golin CE, Fried MW. "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. Dig Dis Sci. 2022 Jan;67(1):100-120. doi: 10.1007/s10620-021-06829-2. Epub 2021 Feb 02. PMID: 33528686; PMCID: PMC8326296.
Copy Download .nbib Format: NLM
Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.

Cancer research

Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A.
PMID: 34711612
Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28.

Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer. Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to breast...

Cite
Patel A, García-Closas M, Olshan AF, et al. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2021;82(1):25-35doi: 10.1158/0008-5472.CAN-21-1207.
Patel, A., García-Closas, M., Olshan, A. F., Perou, C. M., Troester, M. A., Love, M. I., & Bhattacharya, A. (2022). Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer research, 82(1), 25-35. https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel, Achal, et al. "Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer." Cancer research vol. 82,1 (2022): 25-35. doi: https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28. PMID: 34711612; PMCID: PMC8732329.
Copy Download .nbib Format: NLM
Controlling Amphiphilic Polymer Folding beyond the Primary Structure with Protein-Mimetic Di(Phenylalanine).

Journal of the American Chemical Society

Warren JL, Dykeman-Bermingham PA, Knight AS.
PMID: 34375094
J Am Chem Soc. 2021 Aug 25;143(33):13228-13234. doi: 10.1021/jacs.1c05659. Epub 2021 Aug 10.

While methods for polymer synthesis have proliferated, their functionality pales in comparison to natural biopolymers-strategies are limited for building the intricate network of noncovalent interactions necessary to elicit complex, protein-like functions. Using a bioinspired di(phenylalanine) acrylamide (FF) monomer, we...

Cite
Warren JL, Dykeman-Bermingham PA, Knight AS. Controlling Amphiphilic Polymer Folding beyond the Primary Structure with Protein-Mimetic Di(Phenylalanine). J Am Chem Soc. 2021;143(33):13228-13234doi: 10.1021/jacs.1c05659.
Warren, J. L., Dykeman-Bermingham, P. A., & Knight, A. S. (2021). Controlling Amphiphilic Polymer Folding beyond the Primary Structure with Protein-Mimetic Di(Phenylalanine). Journal of the American Chemical Society, 143(33), 13228-13234. https://doi.org/10.1021/jacs.1c05659
Warren, Jacqueline L, et al. "Controlling Amphiphilic Polymer Folding beyond the Primary Structure with Protein-Mimetic Di(Phenylalanine)." Journal of the American Chemical Society vol. 143,33 (2021): 13228-13234. doi: https://doi.org/10.1021/jacs.1c05659
Warren JL, Dykeman-Bermingham PA, Knight AS. Controlling Amphiphilic Polymer Folding beyond the Primary Structure with Protein-Mimetic Di(Phenylalanine). J Am Chem Soc. 2021 Aug 25;143(33):13228-13234. doi: 10.1021/jacs.1c05659. Epub 2021 Aug 10. PMID: 34375094.
Copy Download .nbib Format: NLM
Evaluating cytokine production by flow cytometry using brefeldin A in mice.

STAR protocols

Kovacs SB, Oh C, Aachoui Y, Miao EA.
PMID: 33458706
STAR Protoc. 2020 Dec 30;2(1):100244. doi: 10.1016/j.xpro.2020.100244. eCollection 2021 Mar 19.

Characterizing cytokine production

Cite
Kovacs SB, Oh C, Aachoui Y, et al. Evaluating cytokine production by flow cytometry using brefeldin A in mice. STAR Protoc. 2020;2(1):100244doi: 10.1016/j.xpro.2020.100244.
Kovacs, S. B., Oh, C., Aachoui, Y., & Miao, E. A. (2021). Evaluating cytokine production by flow cytometry using brefeldin A in mice. STAR protocols, 2(1), 100244. https://doi.org/10.1016/j.xpro.2020.100244
Kovacs, Stephen B, et al. "Evaluating cytokine production by flow cytometry using brefeldin A in mice." STAR protocols vol. 2,1 (2021): 100244. doi: https://doi.org/10.1016/j.xpro.2020.100244
Kovacs SB, Oh C, Aachoui Y, Miao EA. Evaluating cytokine production by flow cytometry using brefeldin A in mice. STAR Protoc. 2020 Dec 30;2(1):100244. doi: 10.1016/j.xpro.2020.100244. eCollection 2021 Mar 19. PMID: 33458706; PMCID: PMC7797915.
Copy Download .nbib Format: NLM
β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma.

Cancers

Coleman MF, Liu KA, Pfeil AJ, Etigunta SK, Tang X, Fabela S, Lashinger LM, Cui Z, Hursting SD.
PMID: 34944981
Cancers (Basel). 2021 Dec 18;13(24). doi: 10.3390/cancers13246359.

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the United States, and effective therapies for PDAC are currently lacking. Moreover, PDAC is promoted and exacerbated by obesity, while cachexia and sarcopenia are exceptionally common...

Cite
Coleman MF, Liu KA, Pfeil AJ, et al. β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246359.
Coleman, M. F., Liu, K. A., Pfeil, A. J., Etigunta, S. K., Tang, X., Fabela, S., Lashinger, L. M., Cui, Z., & Hursting, S. D. (2021). β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma. Cancers, 13(24), . https://doi.org/10.3390/cancers13246359
Coleman, Michael F, et al. "β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246359
Coleman MF, Liu KA, Pfeil AJ, Etigunta SK, Tang X, Fabela S, Lashinger LM, Cui Z, Hursting SD. β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021 Dec 18;13(24). doi: 10.3390/cancers13246359. PMID: 34944981; PMCID: PMC8699071.
Copy Download .nbib Format: NLM
Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth.

Translational oncology

Das M, Zhou X, Liu Y, Das A, Vincent BG, Li J, Liu R, Huang L.
PMID: 32862105
Transl Oncol. 2020 Dec;13(12):100856. doi: 10.1016/j.tranon.2020.100856. Epub 2020 Aug 28.

The immunogenic clonal-fraction threshold in heterogeneous solid-tumor required to induce effective bystander-killing of non-immunogenic subclones is unknown. Pancreatic cancer poses crucial challenges for immune therapeutic interventions due to low mutational-burden and consequent lack of neoantigens. Here, we designed a...

Cite
Das M, Zhou X, Liu Y, et al. Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Transl Oncol. 2020;13(12):100856doi: 10.1016/j.tranon.2020.100856.
Das, M., Zhou, X., Liu, Y., Das, A., Vincent, B. G., Li, J., Liu, R., & Huang, L. (2020). Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Translational oncology, 13(12), 100856. https://doi.org/10.1016/j.tranon.2020.100856
Das, Manisit, et al. "Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth." Translational oncology vol. 13,12 (2020): 100856. doi: https://doi.org/10.1016/j.tranon.2020.100856
Das M, Zhou X, Liu Y, Das A, Vincent BG, Li J, Liu R, Huang L. Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Transl Oncol. 2020 Dec;13(12):100856. doi: 10.1016/j.tranon.2020.100856. Epub 2020 Aug 28. PMID: 32862105; PMCID: PMC7475277.
Copy Download .nbib Format: NLM
Antiapoptotic Bcl-2 family proteins BCL-xL and MCL-1 integrate neural progenitor survival and proliferation during postnatal cerebellar neurogenesis.

Cell death and differentiation

Veleta KA, Cleveland AH, Babcock BR, He YW, Hwang D, Sokolsky-Papkov M, Gershon TR.
PMID: 33293647
Cell Death Differ. 2021 May;28(5):1579-1592. doi: 10.1038/s41418-020-00687-7. Epub 2020 Dec 08.

The tendency of brain cells to undergo apoptosis in response to exogenous events varies across neural development, with apoptotic threshold dependent on proliferation state. Proliferative neural progenitors show a low threshold for apoptosis, while terminally differentiated neurons are relatively...

Cite
Veleta KA, Cleveland AH, Babcock BR, et al. Antiapoptotic Bcl-2 family proteins BCL-xL and MCL-1 integrate neural progenitor survival and proliferation during postnatal cerebellar neurogenesis. Cell Death Differ. 2020;28(5):1579-1592doi: 10.1038/s41418-020-00687-7.
Veleta, K. A., Cleveland, A. H., Babcock, B. R., He, Y. W., Hwang, D., Sokolsky-Papkov, M., & Gershon, T. R. (2021). Antiapoptotic Bcl-2 family proteins BCL-xL and MCL-1 integrate neural progenitor survival and proliferation during postnatal cerebellar neurogenesis. Cell death and differentiation, 28(5), 1579-1592. https://doi.org/10.1038/s41418-020-00687-7
Veleta, Katherine A, et al. "Antiapoptotic Bcl-2 family proteins BCL-xL and MCL-1 integrate neural progenitor survival and proliferation during postnatal cerebellar neurogenesis." Cell death and differentiation vol. 28,5 (2021): 1579-1592. doi: https://doi.org/10.1038/s41418-020-00687-7
Veleta KA, Cleveland AH, Babcock BR, He YW, Hwang D, Sokolsky-Papkov M, Gershon TR. Antiapoptotic Bcl-2 family proteins BCL-xL and MCL-1 integrate neural progenitor survival and proliferation during postnatal cerebellar neurogenesis. Cell Death Differ. 2021 May;28(5):1579-1592. doi: 10.1038/s41418-020-00687-7. Epub 2020 Dec 08. PMID: 33293647; PMCID: PMC8166857.
Copy Download .nbib Format: NLM
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

bioRxiv : the preprint server for biology

Schäfer A, Martinez DR, Won JJ, Moreira FR, Brown AJ, Gully KL, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett KT, Bleier BJ, Bannister R, Feng JY, Bilello JP, Cihlar T, Mackman RL, Montgomery SA, Baric RS, Sheahan TP.
PMID: 34545367
bioRxiv. 2021 Sep 17; doi: 10.1101/2021.09.13.460111.

The COVID-19 pandemic remains uncontrolled despite the rapid rollout of safe and effective SARS-CoV-2 vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common...

Cite
Schäfer A, Martinez DR, Won JJ, et al. Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice. bioRxiv. 2021;doi: 10.1101/2021.09.13.460111.
Schäfer, A., Martinez, D. R., Won, J. J., Moreira, F. R., Brown, A. J., Gully, K. L., Kalla, R., Chun, K., Du Pont, V., Babusis, D., Tang, J., Murakami, E., Subramanian, R., Barrett, K. T., Bleier, B. J., Bannister, R., Feng, J. Y., Bilello, J. P., Cihlar, T., Mackman, R. L., Montgomery, S. A., Baric, R. S., & Sheahan, T. P. (2021). Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.09.13.460111
Schäfer, Alexandra, et al. "Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.09.13.460111
Schäfer A, Martinez DR, Won JJ, Moreira FR, Brown AJ, Gully KL, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett KT, Bleier BJ, Bannister R, Feng JY, Bilello JP, Cihlar T, Mackman RL, Montgomery SA, Baric RS, Sheahan TP. Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice. bioRxiv. 2021 Sep 17; doi: 10.1101/2021.09.13.460111. PMID: 34545367; PMCID: PMC8452096.
Copy Download .nbib Format: NLM
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells.

Journal for immunotherapy of cancer

Huckaby JT, Landoni E, Jacobs TM, Savoldo B, Dotti G, Lai SK.
PMID: 34518288
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002737.

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise as a personalized cellular immunotherapy against B cell malignancies. However, the complex and lengthy manufacturing processes involved in generating CAR T cell products ex vivo result in substantial...

Cite
Huckaby JT, Landoni E, Jacobs TM, et al. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer. 2021;9(9)doi: 10.1136/jitc-2021-002737.
Huckaby, J. T., Landoni, E., Jacobs, T. M., Savoldo, B., Dotti, G., & Lai, S. K. (2021). Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. Journal for immunotherapy of cancer, 9(9), . https://doi.org/10.1136/jitc-2021-002737
Huckaby, Justin T, et al. "Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells." Journal for immunotherapy of cancer vol. 9,9 (2021). doi: https://doi.org/10.1136/jitc-2021-002737
Huckaby JT, Landoni E, Jacobs TM, Savoldo B, Dotti G, Lai SK. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002737. PMID: 34518288; PMCID: PMC8438880.
Copy Download .nbib Format: NLM
Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer.

Annals of surgical oncology

Duchesneau ED, An SJ, Strassle PD, Reeder-Hayes KE, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM.
PMID: 35039947
Ann Surg Oncol. 2022 Jan 17; doi: 10.1245/s10434-021-11260-y. Epub 2022 Jan 17.

BACKGROUND: The optimal treatment strategy for small node-negative human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains controversial. Neoadjuvant chemotherapy may risk overtreatment, whereas surgery first fails to identify patients with residual disease in need of escalated adjuvant...

Cite
Duchesneau ED, An SJ, Strassle PD, et al. Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer. Ann Surg Oncol. 2022;doi: 10.1245/s10434-021-11260-y.
Duchesneau, E. D., An, S. J., Strassle, P. D., Reeder-Hayes, K. E., Gallagher, K. K., Ollila, D. W., Downs-Canner, S. M., & Spanheimer, P. M. (2022). Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer. Annals of surgical oncology, . https://doi.org/10.1245/s10434-021-11260-y
Duchesneau, Emilie D, et al. "Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer." Annals of surgical oncology vol. (2022). doi: https://doi.org/10.1245/s10434-021-11260-y
Duchesneau ED, An SJ, Strassle PD, Reeder-Hayes KE, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM. Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer. Ann Surg Oncol. 2022 Jan 17; doi: 10.1245/s10434-021-11260-y. Epub 2022 Jan 17. PMID: 35039947.
Copy Download .nbib Format: NLM
KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface.

iScience

Yin G, Zhang J, Nair V, Truong V, Chaia A, Petela J, Harrison J, Gorfe AA, Campbell SL.
PMID: 32882514
iScience. 2020 Aug 10;23(9):101448. doi: 10.1016/j.isci.2020.101448. Epub 2020 Aug 10.

RAS proteins function as highly regulated molecular switches that control cellular growth. In addition to regulatory proteins, RAS undergoes a number of posttranslational modifications (PTMs) that regulate its activity. Lysine 104, a hot spot for multiple PTMs, is a...

Cite
Yin G, Zhang J, Nair V, et al. KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface. iScience. 2020;23(9):101448doi: 10.1016/j.isci.2020.101448.
Yin, G., Zhang, J., Nair, V., Truong, V., Chaia, A., Petela, J., Harrison, J., Gorfe, A. A., & Campbell, S. L. (2020). KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface. iScience, 23(9), 101448. https://doi.org/10.1016/j.isci.2020.101448
Yin, Guowei, et al. "KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface." iScience vol. 23,9 (2020): 101448. doi: https://doi.org/10.1016/j.isci.2020.101448
Yin G, Zhang J, Nair V, Truong V, Chaia A, Petela J, Harrison J, Gorfe AA, Campbell SL. KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface. iScience. 2020 Aug 10;23(9):101448. doi: 10.1016/j.isci.2020.101448. Epub 2020 Aug 10. PMID: 32882514; PMCID: PMC7479270.
Copy Download .nbib Format: NLM
Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.

Research square

Wahl A, Gralinski L, Johnson C, Yao W, Kovarova M, Dinnon K, Liu H, Madden V, Krzystek H, De C, White K, Schäfer A, Zaman T, Leist S, Grant P, Gully K, Askin F, Browne E, Jones C, Pickles R, Baric R, Garcia JV.
PMID: 32995766
Res Sq. 2020 Sep 24; doi: 10.21203/rs.3.rs-80404/v1.

All known recently emerged human coronaviruses likely originated in bats. Here, we used a single experimental platform based on human lung-only mice (LoM) to demonstrate efficient in vivo replication of all recently emerged human coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2) and...

Cite
Wahl A, Gralinski L, Johnson C, et al. Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801. Res Sq. 2020;doi: 10.21203/rs.3.rs-80404/v1.
Wahl, A., Gralinski, L., Johnson, C., Yao, W., Kovarova, M., Dinnon, K., Liu, H., Madden, V., Krzystek, H., De, C., White, K., Schäfer, A., Zaman, T., Leist, S., Grant, P., Gully, K., Askin, F., Browne, E., Jones, C., Pickles, R., Baric, R., & Garcia, J. V. (2020). Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801. Research square, . https://doi.org/10.21203/rs.3.rs-80404/v1
Wahl, Angela, et al. "Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801." Research square vol. (2020). doi: https://doi.org/10.21203/rs.3.rs-80404/v1
Wahl A, Gralinski L, Johnson C, Yao W, Kovarova M, Dinnon K, Liu H, Madden V, Krzystek H, De C, White K, Schäfer A, Zaman T, Leist S, Grant P, Gully K, Askin F, Browne E, Jones C, Pickles R, Baric R, Garcia JV. Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801. Res Sq. 2020 Sep 24; doi: 10.21203/rs.3.rs-80404/v1. PMID: 32995766; PMCID: PMC7523135.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 239 entries